Ashkan Shoamanesh: Thrilled to Be Leading The Global INTERCEPT Trial
Ashkan Shoamanesh, Associate Professor of Medicine (Neurology), Marta and Owen Boris Chair in Stroke Research and Care at McMaster University, reposted from Hamilton Health Sciences on LinkedIn:
”Thrilled to be leading the global INTERCEPT trial alongside Alexander Benz and PJ Devereaux.
This trial addresses a major unmet need in patients with stroke and atrial fibrillation who continue to face a cumulative 5-year risk of recurrent stroke of 20–25% despite best medical therapy, including anticoagulation.
The Vine carotid filter system from Javelin Medical is a simple yet sophisticated device designed to prevent the most disabling and life-threatening recurrent strokes in these patients.
The device is implanted percutaneously through a fine needle under ultrasound guidance and does not require anaesthesia.
We are now expanding the trial to ~200 sites across 20 countries and have been thrilled with the outstanding early performance at Hamilton Health Sciences under the leadership of Aristeidis Katsanos, Brian van Adel, and Bill Wang, with Hamilton Health Sciences being the first hospital to ever perform this procedure outside of Europe.”
Quoting Hamilton Health Sciences‘s post:
”Filters keep coffee fresh, water clean, and cars running smoothly.
Now, a team of Hamilton Health Sciences doctors and researchers are using that same concept to prevent strokes, by placing tiny filters in patients’ carotid arteries at each side of the neck to trap blood clots so they can’t reach the brain.
We’re the first hospital site in North America and most of the world to perform this innovative new procedure to investigate whether these tiny filters, called Vine carotid filters, can lower the number of strokes caused by large vessel blockages inside the brain.
Read more about this global, Phase 3 clinical trial is taking place through a partnership with a medical device company and our Hamilton General Hospital’s stroke and neuro-intervention teams.”

Stay updated with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series